Thumbs up for Novo Nordisk obesity drug

The decision is an important step towards its release in the US

The Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the American Food and Drug Administration (FDA) has voted in favour of approving Novo Nordisk’s new product Saxenda, a drug for the treatment of obesity, the company announced in a press release yesterday.

The panel voted in favour of the drug by a convincing 14 to 1, an important step in the process of getting the drug approved for sale in the lucrative American market.

“We are pleased with the clear recommendation from the advisory committee,” Mads Krogsgaard Thomsen, the company’s chief science officer, said in the press release.

Happy shareholders
“We look forward to working with the FDA as they complete their review of Saxenda. Obesity is a serious public health issue in the US and we are committed to making Saxenda a new treatment option for adults with obesity.”

Børsen reports that the news was also greeted favourably by the company’s shareholders, including the pension company PFA, which reportedly has 4.5 billion kroner at stake.

Jesper Langmack, the head of PFA, told Børsen that the share price has risen in expectation of FDA approval. “It will rise even more this morning,” he said. “So we’re of course very happy about the news, even though a no wouldn’t have changed our long-term view of Novo – just reduced potential in the share price.”

The new drug application (NDA) for Saxenda was submitted by Novo Nordisk to the FDA on 20 December 2013.

TOP STORIES

Connect club

Connect Club is your gateway to a vibrant programme of events and an international community in Denmark.

Sign up here

Career

  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.

Want to advertise your job with CPH Post?

Contact us

Jobs